Research output per year
Research output per year
Personal profile
specialisation
Pediatric Hematology
Research interests
Patients with severe hemophilia A can be effectively treated by intravenous administration of the deficient coagulation factor VIII (FVIII). However, in about 25-35% of patients, treatment is complicated by the development of neutralizing alloantibodies, called inhibitors. Eradication of inhibitors can be achieved by repeated administration of high-dose therapeutic FVIII, called immune tollerance induction (ITI). Unfortunately, this approach is only effective in about 70% of patients.
GO ITI Study Genetic determinants of the Outcome of Immune Tolerance Induction therapy in patients with severe hemophilia A and inhibitors.
The aim of this study is to identify genetic determinants that are associated with successful immune tolerance induction in patients with hemophilia A and inhibitors.
GRIP Study The role of Fc Gamma Receptors in Immune tolerance to factor VIII Protein.
This project aims to determine how the interaction of FVIII immune complexes with FcyRs directs the response of dendritic cells.
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A
Oomen, I., Verhagen, M., Miranda, M., Allacher, P., Beckers, E. A. M., Blijlevens, N. M. A., Bom, J. G. V. D., Coppens, M., Driessens, M., Eikenboom, J. C. J., Fijnvandraat, K., Hassan, S., van Heerde, W. L., Hooimeijer, H. L., Jansen, J. H., Kaijen, P., Leebeek, F. W. G., Meijer, D., Paul, H., Rijpma, S. R., & 6 others, 2024, In: Frontiers in immunology. 15, 1355813.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis
International Genetic and clinical determinants of the Outcome of Immune Tolerance Induction (GO-ITI) study group, 1 Jan 2023, In: Research and practice in thrombosis and haemostasis. 7, 1, p. 100020 100020.Research output: Contribution to journal › Article › Academic › peer-review
Open Access3 Citations (Scopus) -
Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases
Oomen, I., Rashid, A. N-S., Bouts, A. H. M., Gouw, S. C., Kuijpers, T. W., Rispens, T., de Vries, A., Wolbink, G., van den Berg, J. M. & Schonenberg-Meinema, D., 1 Sept 2021, In: Clinical and experimental rheumatology. 39, 5, p. 183-190 8 p.Research output: Contribution to journal › Article › Academic › peer-review
7 Citations (Scopus) -
Back to base pairs: What is the genetic risk for red bloodcell alloimmunization?
SCORE consortium, Jul 2021, In: Blood Reviews. 48, 100794.Research output: Contribution to journal › Review article › Academic › peer-review
Open Access4 Citations (Scopus)